

GYNECOLOGY DISEASE SITE COMMITTEE

DISEASE SITE COMMITTEE MEETING AGENDA

CHELSEA HOTEL, TORONTO, ON

ROOM: ROSSETTI

SATURDAY APRIL 26, 2025 8:30 AM– 12:00 PM EST

CO-CHAIRS : MARK CAREY AND STEPHEN WELCH
SENIOR INVESTIGATOR: WENDY PARULEKAR

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To define key design elements of a pragmatic trial in oncology and identify opportunities for concept development and trial conduct.
- To identify and address, through clinical trial and translational research, the disease burden associated with gynaecological malignancies in Canada.
- To identify clinical trial research opportunities within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct.
- To apply best practices in clinical trials conduct and analysis to the Canadian Cancer Trials Group research agenda.
- To identify mentoring opportunities within the Canadian Cancer Trials Group research agenda for new investigators.

8:30 am	Welcome / Announcements	M. Carey / S. Welch
8:40 am	Pragmatic Trials: GCIG – Planning and Perspectives	M. Bookman
9:00 am	Panel and Audience Discussion on Pragmatic Trials	
9:20 am	Cervical Working Group	E. Leung / V. Samouelian
10:05 am	Break	
10:20 am	IND report	JL. Ethier



10:30 am	Endometrial Working Group	J. McAlpine / K. Han
11:25 am	Ovarian Working Group	S. Lau / A. Tinker
11:40 am	Correlative Science, QOL, and Economics Reports	H. MacKay/ I. Kong/ J. Kwon
11:55 am	Closing Remarks	M. Carey / S. Welch
12:00 pm	Meeting Adjourned	



Canadian
Cancer
Society

Société
canadienne
du cancer

CCTG is a CCS national program.

GYNE Publications
January 2024 – April 2025

1. Kwon JS, McTaggart-Cowan H, Ferguson SE, Samouëlian V, Lambaudie E, Guyon F, Tidy J, Williamson K, Gleeson N, de Kroon C, van Driel W, Mahner S, Hanker L, Goffin F, Berger R, Eyjólfssdóttir B, Kim J-W, Brotto LA, Pataky R, Yeung SST, Chan KKW, Cheung MC, Ubi J, Tu D, Shepherd LE, Plante M. Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial. *J Gynecol Oncol* 35: e117. 2024.
2. Kwon JS, Plante M, Ferguson S, McTaggart-Cowan H, Samouëlian V, Ferron G, Maulard A, Lambaudie E, Tidy J, Williamson K, Gleeson N, Brotto L, Yeung S, Khabra N, Pataky R, Chan K, Cheung M, Ubi J, Tu D, Shepherd LE. Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer from the CCTG CX.5 'SHAPE' phase III clinical trial. *ESGO Congress. Journal of Gynecological Cancer* 34 [Suppl 1], 2024.
3. Lee J-M, Brady MF, Miller A, Moore RG, MacKay H, McNally L, Lea J, Street D, Lheureux S, McDonald ME, Duska LR, Cantuaria G, Kavecansky J, Leath CA, Powell M, Cadungog MG, Rose PG, Kim Y-M, Huang HQ, Provencher M, Wenzel LB, Bookman MA, Kohn EC, Alvarez Secord A. Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005. *Journal of Clinical Oncology* 42: 4305-4316. 2024.
4. Mahner S, Trillsch F, Kwon J, Ferguson SE, Bessette P, Ferron G, Maulard A, De Kroon C, Van Driel WJ, Tidy J, Williamson K, Goffin F, Polterauer S, Eyjólfssdóttir B, Kim J-W, Maguire PJ, Schmalfeldt B, Tu D, Shepherd L, Plante M. Surgical approach, preoperative LEEP/cone biopsy and patterns of recurrence and death in low-risk cervical cancer – analysis of the international CCTG CX.5/SHAPE phase III trial. *ESGO Congress. International Journal of Gynecological Cancer* 34 [Suppl 1], 2024.
5. Mell LK, Deng W, Gao L, Kunos CM, Chino JP, Quick AM, Feddock JM, Donnelly ED, Albuquerque KV, Leif JL, Richardson DL, Amarnath SR, Jegadeesh N, Santos-Reyes LJ, MacKay H, Aghajanian C, Monk BJ, Miller A, Mayadev JS, Leath C. Comparison of Image-Guided Intensity Modulated Radiotherapy (IG-IMRT) vs. Conventional Radiotherapy (4FRT) for Locoregionally Advanced Cervical Cancer on the NRG GY006 Trial. *ASTRO. International Journal of Radiation Oncology, Biology, Physics* 120 [2], S112-S113. 2024.
6. Nicum S, Ledermann JA, Mileschkin L, Jayson GC, Gourley C, Michael A, Lord R, Mackay H, Hall M, Tookman L, Banerjee S, Harnett P, Macdonald I, Lee YC, Elyashiv O, Wilkinson K, Farrelly L, Counsell N. LBA33 ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy. *ESMO Congress 2024. Annals of Oncology* 35 S1225-S1226. 2024.
7. Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, de Kroon C, Van Driel W, Tidy J, Williamson K, Mahner S, Kommos S, Goffin F, Tamussino K, Eyjólfssdóttir B, Kim J-W, Gleeson N, Brotto L, Tu D, Shepherd LE. Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer. *New England Journal of Medicine* 390: 819-829. 2024.
8. Plante M, Mahner S, Ferron G. Simple versus Radical Hysterectomy for Low-Risk Cervical Cancer. Author response to Letter to Editor. *New England Journal of Medicine*; 2024. p. 1832-1833.



9. Plante M, Mahner S, Sebastianelli A, Bessette P, Lambaudie E, Guyon F, Piek J, Smolders R, Tidy J, Williamson K, Hanker L, Goffin F, Tsibulak I, Eyjolfssdottir B, Gleeson N, Lee J-Y, Kwon J, Ferguson S, Tu D, Shepherd L. PR021/#195 Minimally invasive versus open surgery in patients with low risk cervical cancer who underwent simple hysterectomy; an exploratory analysis from the CCTG cx.5/shape trial cx.5/shape trial. International Gynecologic Cancer Society Annual Global Meeting. International Journal of Gynecological Cancer 34 [Suppl 3], A47-A48. 2024.
10. Trillsch F, Mahner S, Krämer B, Radosa J, Burges A, Schmalfeldt B, Lampe B, Lindner C, Hanker LC, Ulrich UA, Juhasz-Böss I, Hillemanns P, Schochter F, Fehm T, Hasenburg A, Denschlag D, Schröder W, Trojnarzka D, Harter P, Tu D, Shepherd LE, Plante M. Detaillierte Analyse von operativen Parametern im Rahmen der internationalen Phase III-Studie AGO-OP.8/CCTG CX.5/SHAPE. BGGF Kongress. Geburtshilfe Frauenheilkd 84 [06], FV05. 2024.
11. Ferguson SE, Brotto LA, Kwon J, Samouelian V, Ferron G, Maulard A, de Kroon C, Van Driel W, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjolfssdottir B, Kim J-W, Gleeson N, Tu D, Shepherd L, Plante M. Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy. Journal of Clinical Oncology 43: 167-179. 2025.
12. Plante M, Mahner S, Sebastianelli A, Bessette P, Lambaudie E, Guyon F, Piek J, Smolders R, Tidy J, Williamson K, Hanker L, Goffin F, Tsibulak I, Eyjolfssdottir B, Gleeson N, Lee J-Y, Ke Y, Kwon JS, Ferguson SE, Shepherd L, Tu D. Minimally invasive compared to open surgery in patients with low-risk cervical cancer following simple hysterectomy: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial. International Journal of Gynecological Cancer 35: 100001. 2025.

